WEI HU to Bridged-Ring Compounds
This is a "connection" page, showing publications WEI HU has written about Bridged-Ring Compounds.
Connection Strength
0.014
-
A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan. Cancer Chemother Pharmacol. 2004 Jan; 53(1):1-7.
Score: 0.014